Every day we are improving processes, shortening timelines and increasing volumes as we work to bring remdesivir to patients as soon as possible. Our goal is to produce a total of:
More than 140,000 treatment courses by the end of May 2020
More than 500,000 treatment courses by October 2020
More than 1 million treatment courses by December 2020
Several million treatment courses in 2021, if required
https://www.gilead.com/purpose/advan...r-for-covid-19
I also see that a Chinese company has copied the drug and can produce it and would license it from Gilead but who knows if they would allow that. The only thing I saw on a quick look was the Gilead CEO saying they won’t get into a patent dispute.